Medication info
Sitagliptin Metformin Extended-Release Tablet 50/1000 mg

Sitagliptin Metformin Extended-Release Tablet 50/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.69mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Shinpoong Pharmaceutical Co., Ltd.
Appearance
Light green oval extended-release film-coated tablet
Packaging
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Approval status
Active

MFDS item code 202300591 · Approved 2023.02.17 · Insurance code 648508170

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
In antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug should be taken once daily with a meal, preferably in the evening, and the dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. To maintain its extended-release properties, this drug must be swallowed whole and must not be split, crushed, ground, or chewed. Cases have been reported in which the drug was incompletely dissolved and excreted in the feces. It is not known whether the material excreted in the feces contained the active ingredients of the drug. If a patient repeatedly reports finding this drug in the feces, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). Take 1 tablet of this drug 100/1000 mg extended-release tablets once daily. Patients taking this drug 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin treatment: For patients with no prior experience of antidiabetic drug therapy who cannot achieve adequate glycemic control with monotherapy, or who cannot achieve adequate glycemic control with sitagliptin monotherapy, the initial total daily dose of this drug is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see Precautions for Use, 2. Patients in whom this drug must not be administered). 2. Patients receiving metformin treatment: - The recommended initial total daily dose of this drug for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 100 mg and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this drug may start at their current doses of sitagliptin and metformin. - Patients receiving immediate-release tablets at a current metformin dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this drug 50/1000 mg extended-release tablets once daily. 3. Patients unable to achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this drug is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this drug. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment. Treatment should not be initiated with this drug because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug must not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients in whom this drug must not be administered).

Ingredients

Manufacturer
Shinpoong Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used to assist in blood sugar control for patients with type 2 diabetes. When administered along with dietary and exercise therapies, it can effectively manage blood sugar levels. Sitagliptin and metformin work together to reduce and stabilize blood sugar levels. This may also contribute to the prevention of complications associated with diabetes. Therefore, this medication is used for blood sugar control in type 2 diabetes patients.

How to take

Adult dose

In antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug should be taken once daily with a meal, preferably in the evening, and the dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. To maintain its extended-release properties, this drug must be swallowed whole and must not be split, crushed, ground, or chewed. Cases have been reported in which the drug was incompletely dissolved and excreted in the feces. It is not known whether the material excreted in the feces contained the active ingredients of the drug. If a patient repeatedly reports finding this drug in the feces, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). Take 1 tablet of this drug 100/1000 mg extended-release tablets once daily. Patients taking this drug 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin treatment: For patients with no prior experience of antidiabetic drug therapy who cannot achieve adequate glycemic control with monotherapy, or who cannot achieve adequate glycemic control with sitagliptin monotherapy, the initial total daily dose of this drug is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see Precautions for Use, 2. Patients in whom this drug must not be administered). 2. Patients receiving metformin treatment: - The recommended initial total daily dose of this drug for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 100 mg and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this drug may start at their current doses of sitagliptin and metformin. - Patients receiving immediate-release tablets at a current metformin dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this drug 50/1000 mg extended-release tablets once daily. 3. Patients unable to achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this drug is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this drug. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment. Treatment should not be initiated with this drug because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug must not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients in whom this drug must not be administered).

Precautions

This medication contains sitagliptin and metformin. Firstly, serious allergic reactions may occur while taking this medication; if symptoms such as skin rash, hives, or difficulty breathing appear, it is essential to stop taking the medication immediately and consult with a healthcare professional. This medication may cause inflammation of the pancreas known as pancreatitis; therefore, if symptoms such as abdominal pain, nausea, vomiting, loss of appetite, or fever occur, it should be reported to a doctor immediately. Furthermore, the metformin component can cause lactic acidosis, a rare but severe metabolic disorder. Symptoms may include muscle pain, weakness, difficulty breathing, abdominal pain, low body temperature, or altered consciousness; if these symptoms appear, a healthcare facility should be visited immediately. This medication should not be administered to patients with reduced kidney function or liver dysfunction, and it should be stopped in cases of acute illness such as dehydration, severe infection, heart failure, or acute myocardial infarction. In cases where patients are scheduled for iodine contrast imaging tests, they must stop taking this medication 48 hours before the test and can only resume taking it once normal kidney function has been confirmed. Women who are pregnant or may become pregnant, as well as nursing mothers, should not take this medication, and safety for children under 18 has not been established. During the course of taking this medication, irregular meals, excessive exercise, and overconsumption of alcohol should be avoided, and if there are other medications being taken, they should be reported to a doctor or pharmacist due to potential interactions. Symptoms of hypoglycemia (dizziness, cold sweat, trembling, etc.) may occur; especially when taken with insulin or sulfonylurea medications, blood sugar levels should be checked frequently. Regular checks of kidney function, blood tests, and vitamin B12 levels should be conducted; if any unusual symptoms occur, consult with a healthcare professional immediately. Finally, if surgery is approaching or if the patient is in a severe condition such as severe infection or trauma, the medication should be temporarily discontinued, and resumed only after recovery.

Side effects

  • Severe hypersensitivity reactions
  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory tract infection
  • headache
Show 19 more
  • nausea
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe and debilitating arthralgia
  • vesicular pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • elevated liver enzymes
  • acute renal failure
  • rash
  • urticaria
  • cutaneous vasculitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it should be stored in a tightly sealed container. Additionally, it is important to keep it at room temperature between 1 and 30 degrees Celsius to maintain effectiveness.

Appearance and packaging

Appearance

Light green oval extended-release film-coated tablet

Package unit

Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.